51
Participants
Start Date
December 14, 2018
Primary Completion Date
December 23, 2024
Study Completion Date
December 31, 2026
Ribociclib
600 mg by mouth daily for 21 days followed by 7 days off treatment
Letrozole
2.5 mg by mouth daily
Western Pennsylvania Hospital/West Penn Hospital, Pittsburgh
Abington Memorial Hospital, Willow Grove
Northside Hospital, Atlanta
UF Heath, Gainesville
Moffitt Cancer Center, Tampa
The Ohio State Comprehensive Cancer Center, Columbus
Miami Valley Hospital, Centerville
Saint Vincent Hospital and Health Care Center, Inc., Indianapolis
St. Joseph Mercy Hospital Cancer Care Center, Ann Arbor
Mayo Clinic - Rochester, Rochester
NorthShore University HealthSystem, Evanston
University of Oklahoma Health Sciences Center, Oklahoma City
Oklahoma Cancer Care Specialists and Research Institute , LLC, Tulsa
Parkland Health and Hospital System, Dallas
University of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston
Memorial Hermann Texas Medical Center - Texas Medical Center, Houston
Houston Methodist Willowbrook Hospital, Houston
Houston Methodist Hospital, Houston
Houston Methodist Sugar Land Hospital, Sugar Land
New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center, Albuquerque
Southwest Gynecologic Oncology Associates, Albuquerque
University of California, San Francisco, San Francisco
Dartmouth-Hitchcock Medical Center, Lebanon
Hackensack University Medical Center, Hackensack
The Valley Hospital Inc., Ridgewood
Women & Infants Hospital, Providence
Collaborators (1)
Novartis
INDUSTRY
Gynecologic Oncology Group
NETWORK